Radioactive 'Trojan Horse' drug enters brain cancer battle
NCT ID NCT05739942
Summary
This early-stage study is testing a new radioactive drug called [177Lu]Lu-NeoB for glioblastoma, a very aggressive brain cancer. For newly diagnosed patients, the drug is added to standard radiation and chemotherapy. For patients whose cancer has returned, it's given alone. The main goals are to find the safest and most effective dose and see how well the body tolerates it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Mayo Clinic Jacksonville
Jacksonville, Florida, 32224, United States
-
Memorial Sloan Kettering Cancer Ctr
New York, New York, 10065, United States
-
Novartis Investigative Site
Dijon, Cote D Or, 21034, France
-
Novartis Investigative Site
Marseille, 13885, France
-
Novartis Investigative Site
Cologne, North Rhine-Westphalia, 50937, Germany
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
München, 80377, Germany
-
Novartis Investigative Site
Rostock, 18057, Germany
-
Novartis Investigative Site
Jerusalem, 9112001, Israel
-
Novartis Investigative Site
Reggio Emilia, RE, 42123, Italy
-
Novartis Investigative Site
Porto, 4200-072, Portugal
-
Novartis Investigative Site
Granada, Andalusia, 18014, Spain
-
Novartis Investigative Site
Badalona, Catalonia, 08916, Spain
-
Novartis Investigative Site
Barcelona, Catalonia, 08003, Spain
-
Novartis Investigative Site
Barcelona, 08907, Spain
-
Novartis Investigative Site
Madrid, 28009, Spain
-
Novartis Investigative Site
Madrid, 28040, Spain
-
Novartis Investigative Site
Liverpool, CH63 4JY, United Kingdom
-
Uni of Utah Huntsman Cancer Inst
Salt Lake City, Utah, 84103, United States
-
Univ Hosp Cleveland Medical Center
Cleveland, Ohio, 44106-5028, United States
-
University of California LA
Los Angeles, California, 90095, United States
-
University of Colorado Denver
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.